MA54092A - Composés, compositions et procédés de modulation de l'activité de cdk9 - Google Patents
Composés, compositions et procédés de modulation de l'activité de cdk9Info
- Publication number
- MA54092A MA54092A MA054092A MA54092A MA54092A MA 54092 A MA54092 A MA 54092A MA 054092 A MA054092 A MA 054092A MA 54092 A MA54092 A MA 54092A MA 54092 A MA54092 A MA 54092A
- Authority
- MA
- Morocco
- Prior art keywords
- modulating
- compositions
- compounds
- methods
- cdk9 activity
- Prior art date
Links
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 title 1
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862752635P | 2018-10-30 | 2018-10-30 | |
| US201962884993P | 2019-08-09 | 2019-08-09 | |
| US201962910058P | 2019-10-03 | 2019-10-03 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA54092A true MA54092A (fr) | 2021-09-08 |
Family
ID=70328627
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA054092A MA54092A (fr) | 2018-10-30 | 2019-10-29 | Composés, compositions et procédés de modulation de l'activité de cdk9 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US11155560B2 (fr) |
| EP (1) | EP3873911A4 (fr) |
| JP (1) | JP7385658B2 (fr) |
| KR (2) | KR20250174699A (fr) |
| CN (1) | CN112996790B (fr) |
| AU (1) | AU2019370200B2 (fr) |
| BR (1) | BR112021008176A2 (fr) |
| CA (1) | CA3118472A1 (fr) |
| CO (1) | CO2021005502A2 (fr) |
| CR (1) | CR20210202A (fr) |
| DO (1) | DOP2021000066A (fr) |
| IL (1) | IL282254B2 (fr) |
| MA (1) | MA54092A (fr) |
| MD (1) | MD20210033A2 (fr) |
| MX (1) | MX2021004769A (fr) |
| MY (1) | MY210039A (fr) |
| PE (1) | PE20212196A1 (fr) |
| PH (1) | PH12021550857A1 (fr) |
| SG (1) | SG11202104229WA (fr) |
| WO (1) | WO2020092314A1 (fr) |
| ZA (1) | ZA202102609B (fr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11155560B2 (en) * | 2018-10-30 | 2021-10-26 | Kronos Bio, Inc. | Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity |
| US20230158159A1 (en) * | 2020-04-24 | 2023-05-25 | Massachusetts Institute Of Technology | Chimeric degraders of cyclin-dependent kinase 9 and uses thereof |
| JP7814386B2 (ja) * | 2020-11-05 | 2026-02-16 | クロノス バイオ インコーポレイテッド | Ｃｄｋ９活性を調節するための化合物および方法 |
| EP4282868B1 (fr) * | 2021-01-22 | 2026-03-04 | Shanghai Haiyan Pharmaceutical Technology Co., Ltd. | Dérivé de pyrazolo[1,5-a]pyrimidine-7-amine substitué, et compositions et utilisation médicale de celui-ci |
| JP2024543136A (ja) * | 2021-11-24 | 2024-11-19 | クロノス バイオ インコーポレイテッド | （１Ｓ，３Ｓ）－Ｎ１－（５－（ペンタン－３－イル）ピラゾロ［１，５－ａ］ピリミジン－７－イル）シクロペンタン－１，３－ジアミンの多形性形態および塩形態 |
| JP2025527161A (ja) * | 2022-07-22 | 2025-08-20 | 上海海雁醫藥科技有限公司 | 置換されたピラゾロ［１，５－ａ］ピリミジン－７－アミン誘導体の薬学的に許容される塩および多形体、ならびにその使用 |
| WO2025153034A1 (fr) * | 2024-01-19 | 2025-07-24 | 上海海雁医药科技有限公司 | Polymorphe de sel de phosphate de dérivé de pyrazolopyrimidine et son utilisation |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5389632A (en) | 1992-02-24 | 1995-02-14 | Laboratoires Upsa | Pyrazolopyrimidine derivatives which are angiotensin II receptor antagonists |
| WO1995035298A1 (fr) | 1994-06-21 | 1995-12-28 | Otsuka Pharmaceutical Factory, Inc. | DERIVE DE PYRAZOLO[1,5-a]PYRIMIDINE |
| HU229024B1 (en) | 1996-07-24 | 2013-07-29 | Bristol Myers Squibb Pharma Co | Azolo-pyridimidines, pharmaceutical compositions containing the same and use thereof |
| US20010007867A1 (en) | 1999-12-13 | 2001-07-12 | Yuhpyng L. Chen | Substituted 6,5-hetero-bicyclic derivatives |
| CA2379585C (fr) | 1999-09-30 | 2006-06-20 | James W. Darrow | Pyrazolo[1,5,-a]-1,5-pyrimidines a substitution alkylene-diamine et pyrazolo[1,5-a]-1,3,5-triazines |
| ES2277855T3 (es) | 1999-09-30 | 2007-08-01 | Neurogen Corporation | Pirazolo-(1,5-a)-1,5-pirimidinas y pirazolo-(1,5-a)-1,3,5-triazinas amino sustituidas. |
| JP2002308879A (ja) | 2001-04-13 | 2002-10-23 | Nippon Soda Co Ltd | ５−ハロアルキル−アゾロピリミジン化合物、製造方法及び有害生物防除剤 |
| US7662826B2 (en) | 2002-04-23 | 2010-02-16 | Shionogi & Co., Ltd. | Pyrazolo [1,5-a] pyrimidine derivative and nad (p) h oxidase inhibitor containing the same |
| JP2005529919A (ja) | 2002-05-10 | 2005-10-06 | スミスクライン ビーチャム コーポレーション | 治療用化合物 |
| AU2003240488A1 (en) | 2002-06-04 | 2003-12-19 | Neogenesis Pharmaceuticals, Inc. | Pyrazolo` 1,5a! pyrimidine compounds as antiviral agents |
| US7205308B2 (en) | 2002-09-04 | 2007-04-17 | Schering Corporation | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7161003B1 (en) | 2002-09-04 | 2007-01-09 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7563798B2 (en) | 2002-09-04 | 2009-07-21 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| US7196078B2 (en) * | 2002-09-04 | 2007-03-27 | Schering Corpoartion | Trisubstituted and tetrasubstituted pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| US7119200B2 (en) | 2002-09-04 | 2006-10-10 | Schering Corporation | Pyrazolopyrimidines as cyclin dependent kinase inhibitors |
| DE60313872T2 (de) * | 2002-09-04 | 2008-01-17 | Schering Corp. | Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen |
| US7605155B2 (en) * | 2002-09-04 | 2009-10-20 | Schering Corporation | Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors |
| MXPA05002571A (es) * | 2002-09-04 | 2005-09-08 | Schering Corp | Pirazolopirimidinas como inhibidores de cinasa dependientes de ciclina. |
| US8580782B2 (en) | 2002-09-04 | 2013-11-12 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors |
| GB0305559D0 (en) | 2003-03-11 | 2003-04-16 | Teijin Ltd | Compounds |
| US20070179161A1 (en) * | 2003-03-31 | 2007-08-02 | Vernalis (Cambridge) Limited. | Pyrazolopyrimidine compounds and their use in medicine |
| WO2004089471A2 (fr) | 2003-04-11 | 2004-10-21 | Novo Nordisk A/S | Utilisation pharmaceutique de pyrazolo[1,5-a]pyrimidines substituees |
| US7501405B2 (en) | 2003-04-11 | 2009-03-10 | High Point Pharmaceuticals, Llc | Combination therapy using an 11β-hydroxysteroid dehydrogenase type 1 inhibitor and an antihypertensive agent for the treatment of metabolic syndrome and related diseases and disorders |
| JP2005008581A (ja) | 2003-06-20 | 2005-01-13 | Kissei Pharmaceut Co Ltd | 新規なピラゾロ［１，５−ａ］ピリミジン誘導体、それを含有する医薬組成物およびそれらの用途 |
| US20070060595A1 (en) | 2003-10-10 | 2007-03-15 | Toshio Yoshizawa | Novel fused heterocyclic compound and use thereof |
| JP2007515474A (ja) | 2003-12-22 | 2007-06-14 | エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド | Ｃｒｆ受容体アンタゴニストおよびそれらに関連する方法 |
| US8018479B2 (en) | 2008-08-27 | 2011-09-13 | Lexmark International, Inc. | Method and system for correcting the linearity error in electrophotographic devices |
| WO2006016715A1 (fr) * | 2004-08-13 | 2006-02-16 | Teijin Pharma Limited | DÉRIVÉ DE LA PYRAZOLO[1,5-a]PYRIMIDINE |
| CA2591125A1 (fr) | 2004-12-21 | 2006-06-29 | Schering Corporation | Antagonistes de recepteur a2a de pyrazolo [1,5-a]pyrimidine adenosine |
| DE102005007534A1 (de) | 2005-02-17 | 2006-08-31 | Bayer Cropscience Ag | Pyrazolopyrimidine |
| AR057979A1 (es) | 2005-10-06 | 2008-01-09 | Schering Corp | PIRAZOLPIRIMIDINAS COMO INHIBIDORAS DE PROTEíNA QUINASA. COMPOSICIONES FARMACEUTICAS. |
| BRPI0616985B1 (pt) | 2005-10-06 | 2021-10-26 | Merck Sharp & Dohme Corp. | Composto de pirazolo[1,5-a]pirimidina, e, uso de um composto |
| AR056876A1 (es) | 2005-10-21 | 2007-10-31 | Tanabe Seiyaku Co | Compuestos de pirazolo[1-5-a]pirimidina, antagonistas de receptores canabinoides cb1, composiciones farmaceuticas que los contienen y usos en el tratamiento de enfermedades del sistema nervioso central, tales como trastornos psicoticos, neurologicos y similares |
| WO2007109571A2 (fr) | 2006-03-17 | 2007-09-27 | Prometheus Laboratories, Inc. | Procédés de prédiction et de suivi de la thérapie par l'inhibiteur de la tyrosine kinase |
| WO2007139732A1 (fr) | 2006-05-22 | 2007-12-06 | Schering Corporation | Pyrazolo [1, 5-a] pyrimidines en tant qu'inhibiteurs de cdk |
| AU2008261027A1 (en) * | 2007-06-05 | 2008-12-11 | Emory University | Selective inhibitors for cyclin-dependent kinases |
| CN101784276A (zh) | 2007-06-27 | 2010-07-21 | 传染性疾病研究院 | 化合物在用于制备抗结核药剂中的用途 |
| US20110201599A1 (en) * | 2008-07-03 | 2011-08-18 | Exelixis, Inc. | CDK Modulators |
| JP5578490B2 (ja) | 2008-12-26 | 2014-08-27 | 味の素株式会社 | ピラゾロピリミジン化合物 |
| US8993612B2 (en) | 2009-10-08 | 2015-03-31 | Rhizen Pharmaceuticals Sa | Modulators of calcium release-activated calcium channel and methods for treatment of non-small cell lung cancer |
| JP5802676B2 (ja) | 2009-12-04 | 2015-10-28 | センワ バイオサイエンシズ インコーポレイテッド | Ｃｋ２阻害剤としてのピラゾロピリミジンおよび関連複素環化合物 |
| ES2540867T3 (es) | 2010-02-26 | 2015-07-14 | Mitsubishi Tanabe Pharma Corporation | Compuestos de pirazolopirimidina y su uso como inhibidores de PDE10 |
| MY183861A (en) | 2010-03-05 | 2021-03-17 | Kyowa Hakko Kirin Co Ltd | Pyrazolopyrimidine derivative |
| PT3012258T (pt) | 2010-06-24 | 2018-12-14 | Gilead Sciences Inc | Composição farmacêutica compreendendo um derivado de pirazolo[1,5-a]pirimidina como agente antiviral |
| CN110003219A (zh) | 2010-07-13 | 2019-07-12 | 弗·哈夫曼-拉罗切有限公司 | 作为irak4调节剂的吡唑并[1,5a]嘧啶和噻吩并[3,2b]嘧啶衍生物 |
| US8883801B2 (en) | 2010-08-23 | 2014-11-11 | Merck Sharp & Dohme Corp. | Substituted pyrazolo[1,5-a]pyrimidines as mTOR inhibitors |
| WO2012044562A2 (fr) | 2010-09-30 | 2012-04-05 | Merck Sharp & Dohme Corp. | Inhibiteurs de pyrazolopyrimidine pde10 |
| WO2012170827A2 (fr) | 2011-06-08 | 2012-12-13 | Cylene Pharmaceuticals, Inc. | Pyrazolopyrimidines et hétérocycles associés comme inhibiteurs de ck2 |
| WO2013104611A1 (fr) | 2012-01-10 | 2013-07-18 | Bayer Intellectual Property Gmbh | Pyrazolopyrimidines substituées utilisées comme inhibiteurs de l'akt kinase |
| CN104136399B (zh) | 2012-02-17 | 2018-08-07 | 米伦纽姆医药公司 | 泛素活化酶的吡唑并嘧啶基抑制剂 |
| WO2013130943A1 (fr) | 2012-03-02 | 2013-09-06 | Genentech, Inc. | Dérivés sulfonamides amido-benzyliques substitués par un groupe alkyle et disubstitués |
| CA2889919C (fr) | 2012-11-16 | 2021-08-17 | University Health Network | Composes de pyrazolopyrimidine |
| BR112015022864A8 (pt) | 2013-03-14 | 2019-11-26 | Celtaxsys Inc | composto, composição farmacêutica e uso dos mesmos |
| GB201403093D0 (en) | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| EP3125907A4 (fr) | 2014-04-01 | 2017-11-29 | Cornell University | Utilisation d'adn double brin dans des exosomes : un nouveau biomarqueur dans la détection du cancer |
| EP3129371B1 (fr) | 2014-04-05 | 2020-07-29 | Syros Pharmaceuticals, Inc. | Inhibiteurs de kinase cycline-dépendante 7 (cdk7) |
| ES2899196T3 (es) | 2015-03-09 | 2022-03-10 | Aurigene Discovery Tech Ltd | Derivados de pirazolo[1,5-a][1,3,5]triazina y de pirazolo[1,5-a]pirimidina como inhibidores de CDK |
| USRE50776E1 (en) * | 2015-03-27 | 2026-02-03 | Dana-Farber Cancer Institute, Inc. | Inhibitors of cyclin-dependent kinases |
| WO2016169995A1 (fr) | 2015-04-20 | 2016-10-27 | AbbVie Deutschland GmbH & Co. KG | Pyrazolopyrimidines substituées et méthode d'utilisation |
| WO2016201370A1 (fr) * | 2015-06-12 | 2016-12-15 | Dana-Farber Cancer Institute, Inc. | Thérapie d'association utilisant des inhibiteurs de transcription et des inhibiteurs de kinases |
| EP3356330B1 (fr) | 2015-10-01 | 2019-11-20 | Bristol-Myers Squibb Company | Inhibiteurs biaryles de kinases |
| JP2018199623A (ja) | 2015-10-22 | 2018-12-20 | 大正製薬株式会社 | 含窒素縮合複素環化合物 |
| SG10201912607SA (en) | 2015-11-19 | 2020-02-27 | Blueprint Medicines Corp | Compounds and compositions useful for treating disorders related to ntrk |
| US11112410B2 (en) | 2016-04-13 | 2021-09-07 | President And Fellows Of Harvard College | Methods for capturing, isolation, and targeting of circulating tumor cells and diagnostic and therapeutic applications thereof |
| US20190060296A1 (en) * | 2017-07-28 | 2019-02-28 | Massachusetts Institute Of Technology | Discovery of small molecules that target the androgen receptor and uses |
| SI3658557T1 (sl) | 2017-07-28 | 2024-10-30 | Takeda Pharmaceutical Company Limited | Zaviralci TYK2 in njihova uporaba |
| US11155560B2 (en) * | 2018-10-30 | 2021-10-26 | Kronos Bio, Inc. | Substituted pyrazolo[1,5-a]pyrimidines for modulating CDK9 activity |
-
2019
- 2019-10-29 US US16/667,027 patent/US11155560B2/en active Active
- 2019-10-29 KR KR1020257039495A patent/KR20250174699A/ko active Pending
- 2019-10-29 CA CA3118472A patent/CA3118472A1/fr active Pending
- 2019-10-29 WO PCT/US2019/058482 patent/WO2020092314A1/fr not_active Ceased
- 2019-10-29 MY MYPI2021002367A patent/MY210039A/en unknown
- 2019-10-29 EP EP19878830.9A patent/EP3873911A4/fr active Pending
- 2019-10-29 JP JP2021521232A patent/JP7385658B2/ja active Active
- 2019-10-29 BR BR112021008176-3A patent/BR112021008176A2/pt unknown
- 2019-10-29 CR CR20210202A patent/CR20210202A/es unknown
- 2019-10-29 MX MX2021004769A patent/MX2021004769A/es unknown
- 2019-10-29 SG SG11202104229WA patent/SG11202104229WA/en unknown
- 2019-10-29 MA MA054092A patent/MA54092A/fr unknown
- 2019-10-29 MD MDA20210033A patent/MD20210033A2/ro not_active Application Discontinuation
- 2019-10-29 KR KR1020217016498A patent/KR20210068597A/ko active Pending
- 2019-10-29 CN CN201980072853.7A patent/CN112996790B/zh active Active
- 2019-10-29 AU AU2019370200A patent/AU2019370200B2/en not_active Expired - Fee Related
- 2019-10-29 PE PE2021000604A patent/PE20212196A1/es unknown
- 2019-10-29 IL IL282254A patent/IL282254B2/en unknown
-
2021
- 2021-04-14 DO DO2021000066A patent/DOP2021000066A/es unknown
- 2021-04-15 PH PH12021550857A patent/PH12021550857A1/en unknown
- 2021-04-20 ZA ZA2021/02609A patent/ZA202102609B/en unknown
- 2021-04-27 CO CONC2021/0005502A patent/CO2021005502A2/es unknown
- 2021-09-15 US US17/476,237 patent/US11845754B2/en active Active
-
2023
- 2023-11-03 US US18/386,964 patent/US20240132506A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN112996790A (zh) | 2021-06-18 |
| AU2019370200B2 (en) | 2024-12-19 |
| ZA202102609B (en) | 2023-02-22 |
| AU2019370200A1 (en) | 2021-06-10 |
| MX2021004769A (es) | 2021-08-24 |
| KR20210068597A (ko) | 2021-06-09 |
| MD20210033A2 (ro) | 2021-10-31 |
| US11155560B2 (en) | 2021-10-26 |
| PE20212196A1 (es) | 2021-11-16 |
| IL282254A (en) | 2021-05-31 |
| KR20250174699A (ko) | 2025-12-12 |
| US20200131189A1 (en) | 2020-04-30 |
| US20240132506A1 (en) | 2024-04-25 |
| US11845754B2 (en) | 2023-12-19 |
| CA3118472A1 (fr) | 2020-05-07 |
| US20220002305A1 (en) | 2022-01-06 |
| DOP2021000066A (es) | 2021-10-31 |
| JP7385658B2 (ja) | 2023-11-22 |
| WO2020092314A1 (fr) | 2020-05-07 |
| CN112996790B (zh) | 2023-11-03 |
| EP3873911A1 (fr) | 2021-09-08 |
| PH12021550857A1 (en) | 2021-12-06 |
| EP3873911A4 (fr) | 2022-06-22 |
| IL282254B2 (en) | 2025-08-01 |
| JP2022505268A (ja) | 2022-01-14 |
| IL282254B1 (en) | 2025-04-01 |
| MY210039A (en) | 2025-08-22 |
| CO2021005502A2 (es) | 2021-09-20 |
| SG11202104229WA (en) | 2021-05-28 |
| BR112021008176A2 (pt) | 2021-08-03 |
| CR20210202A (es) | 2022-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA54092A (fr) | Composés, compositions et procédés de modulation de l'activité de cdk9 | |
| EP3883577A4 (fr) | Compositions et procédés de modulation de l'activité de la déshydrogénase à chaîne courte | |
| EP3576737A4 (fr) | Compositions et procédés de modulation de l'activité de la déshydrogénase à chaîne courte | |
| EP3638235A4 (fr) | Composés pour moduler l'activité de s1p1 et leurs procédés d'utilisation | |
| UY38685A (es) | Moduladores de la vía de tensión integrada | |
| MA55805A (fr) | Métodes de modulation de l'activité immunitaire | |
| MA53172A (fr) | Composés de sulfonimidamide en tant qu'inhibiteurs de l'activité de l'interleukine 1 | |
| EP3887351A4 (fr) | Composés, compositions et méthodes de modulation de la ferroptose et de traitement de troubles excitotoxiques | |
| MA51670A (fr) | Composés modulant les récepteurs des oestrogènes | |
| EP3317265A4 (fr) | Composés de quinazoline substituée et leurs utilisations pour moduler l'activité de la glucocérébrosidase | |
| EP3359164A4 (fr) | Composés et procédés pour moduler l'expression de l'angiotensinogène | |
| EP4240422A4 (fr) | Composés et procédés de modulation de l'activité de cdk9 | |
| EP3675848A4 (fr) | Composés spirocycliques et procédés de préparation et d'utilisation de ceux-ci | |
| EP3906240A4 (fr) | Compositions et procédés de modulation de la pousse des cheveux | |
| EP4212532A3 (fr) | Analogues de la mitragynine et leurs utilisations | |
| EP3484524A4 (fr) | Composés et procédés de modulation de smn2 | |
| MA54959A (fr) | Composés, compositions et procédés | |
| MA48942A (fr) | Composés thérapeutiques, compositions et procédés d'utilisation associés | |
| MX2021015500A (es) | Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b. | |
| MX2020002435A (es) | Agentes que modulan las funciones de beta-catenina y sus métodos. | |
| EP3349749A4 (fr) | Compositions et méthodes de modulation de l'expression de fmr1 | |
| EP3484310A4 (fr) | Composés, compositions et procédés de modulation de saveur sucrée | |
| IL286681A (en) | Compounds and methods for modulating ube3a-ats | |
| EP3510380A4 (fr) | Composés sondes par activité, compositions et méthodes d'utilisation | |
| EP3793563A4 (fr) | Compositions comprenant des composés de bisfluoroalkyl-1,4-benzodiazépinone et méthodes d'utilisation associées |